1. Home
  2. PCN vs SGMT Comparison

PCN vs SGMT Comparison

Compare PCN & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pimco Corporate & Income Strategy Fund

PCN

Pimco Corporate & Income Strategy Fund

SELL

Current Price

$10.70

Market Cap

805.4M

Sector

Finance

ML Signal

SELL

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$8.17

Market Cap

648.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCN
SGMT
Founded
N/A
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
805.4M
648.1M
IPO Year
2001
2021

Fundamental Metrics

Financial Performance
Metric
PCN
SGMT
Price
$10.70
$8.17
Analyst Decision
Buy
Analyst Count
0
12
Target Price
N/A
★ $27.91
AVG Volume (30 Days)
572.1K
★ 1.3M
Earning Date
01-01-0001
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $2,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.44
$4.50
52 Week High
$13.19
$11.45

Technical Indicators

Market Signals
Indicator
PCN
SGMT
Relative Strength Index (RSI) 41.04 38.30
Support Level $10.44 $6.21
Resistance Level $11.98 $11.33
Average True Range (ATR) 0.18 0.61
MACD 0.02 -0.17
Stochastic Oscillator 44.12 19.74

Price Performance

Historical Comparison
PCN
SGMT

About PCN Pimco Corporate & Income Strategy Fund

PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: